Silvina G Rubio

US Patent:

20120220629, Aug 30, 2012

Filed:

Feb 24, 2012

Appl. No.:

13/404165

Inventors:

Silvina GARCIA RUBIO - Princeton NJ, US
Claudio Pietra - Como, IT
Claudio Giuliano - Como, IT
Zhigang Li - Shanghai, CN

International Classification:

A61K 31/4468
A61P 3/04
A61P 3/10
A61P 3/00
A61P 9/04
A61P 21/00
A61P 1/16
A61P 11/00
A61P 1/00
A61P 25/30
A61P 3/08
A61P 5/48
A61P 3/06
A61P 9/10
A61P 9/00
A61P 25/00
A61P 9/12
A61P 7/00
A61P 1/04
A61P 25/32
A61P 25/36
C07D 211/58

US Classification:

514319, 546206, 546224, 514329

Abstract:

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general formula (I):

US Patent:

20100317581, Dec 16, 2010

Filed:

Jun 8, 2010

Appl. No.:

12/796001

Inventors:

Silvina Garcia Rubio - Princeton NJ, US
Daniel E. Beidler - Poway CA, US
Helle Weibel - Hillerod, DK
Riccardo Braglia - Lugano-Carabbia, CH

Assignee:

Helsinn Therapeutics (U.S.), Inc. - Bridgewater NJ

International Classification:

A61K 38/27
A61P 5/00
A61P 43/00

US Classification:

514 113

Abstract:

Injection and infusion solutions of ipamorelin, having the following composition:

US Patent:

20200276259, Sep 3, 2020

Filed:

Jan 24, 2020

Appl. No.:

16/751836

Inventors:

- Lugano/Pazzallo, CH
- Osaka, JP
Hideyuki Yoshiyama - Osaka, JP
Seemon Pines - Newton PA, US
Eleanor de Groot - Houston TX, US
Silvina Garcia Rubio - Princeton NJ, US
Peter Manini - Giubiasco, CH

International Classification:

A61K 38/05
C07D 401/06
A61P 3/04
C07D 401/12
C07K 5/062
A61K 9/16

Abstract:

The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.

US Patent:

20200262850, Aug 20, 2020

Filed:

Jan 24, 2020

Appl. No.:

16/751823

Inventors:

- Lugano/Pazzallo, CH
Silvina Garcia Rubio - Princeton NJ, US
Antoine Daina - Lausanne, CH
Angelo Guainazzi - Iselin NJ, US
Claudio Pietra - Como, IT

International Classification:

C07F 7/08
C07D 417/12
C07D 413/12
C07D 409/12
C07D 405/14
C07D 241/12
C07D 213/00
C07D 211/96
C07D 211/94
C07D 211/60
C07D 401/06
C07D 471/04
C07D 403/12
C07D 405/12
C07D 239/26
C07D 409/14
C07D 417/14
C07D 401/12
C07D 211/58
C07D 401/14

Abstract:

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I:or pharmaceutically acceptable salts thereof.

US Patent:

20190231843, Aug 1, 2019

Filed:

Apr 14, 2019

Appl. No.:

16/383623

Inventors:

- Lugano/Pazzallo, CH
- Osaka, JP
Hideyuki Yoshiyama - Osaka, JP
Seemon Pines - Newton PA, US
Eleanor de Groot - Houston TX, US
Silvina Garcia Rubio - Princeton NJ, US
Peter Manini - Giubiasco, CH

International Classification:

A61K 38/05
A61K 9/16
C07D 401/12
C07D 401/06
C07K 5/062

Abstract:

The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.

US Patent:

20190062352, Feb 28, 2019

Filed:

Feb 6, 2018

Appl. No.:

15/889589

Inventors:

- Lugano/Pazzallo, CH
Silvina Garcia Rubio - Princeton NJ, US
Antoine Daina - Lausanne, CH
Angelo Guainazzi - Iselin NJ, US
Claudio Pietra - Como, IT

International Classification:

C07F 7/08
C07D 471/04
C07D 401/06
C07D 405/12
C07D 239/26
C07D 409/14
C07D 417/14
C07D 401/12
C07D 211/58
C07D 401/14
C07D 409/12
C07D 413/12
C07D 417/12
C07D 241/12
C07D 405/14
C07D 213/00
C07D 211/96
C07D 211/94
C07D 211/60
C07D 403/12

Abstract:

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I:or pharmaceutically acceptable salts thereof.

US Patent:

20190000914, Jan 3, 2019

Filed:

Apr 26, 2018

Appl. No.:

15/963284

Inventors:

- Lugano/Pazzallo, CH
- Osaka, JP
Hideyuki Yoshiyama - Osaka, JP
Seemon Pines - Newton PA, US
Eleanor de Groot - Houston TX, US
Silvina Garcia Rubio - Princeton NJ, US
Peter Manini - Giubiasco, CH

International Classification:

A61K 38/05
A61K 9/16
C07K 5/062
C07D 401/12
C07D 401/06

Abstract:

The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.

US Patent:

20170145038, May 25, 2017

Filed:

Dec 2, 2016

Appl. No.:

15/368362

Inventors:

- LUGANO/PAZZALLO, CH
Silvina Garcia Rubio - Princeton NJ, US
Antoine Daina - Lausanne, CH
Angelo Guainazzi - Iselin NJ, US
Claudio Pietra - Como, IT

International Classification:

C07F 7/08
C07D 401/12
C07D 401/14
C07D 417/14
C07D 409/14
C07D 239/26
C07D 405/12
C07D 405/14
C07D 403/12
C07D 241/12
C07D 409/12
C07D 417/12
C07D 413/12
C07D 471/04
C07D 211/58

Abstract:

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I:or pharmaceutically acceptable salts thereof.